STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Axsome Therapeutics, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

RTW Investments, LP and Roderick Wong disclose a 3.1% stake in Axsome Therapeutics. The filing reports ownership of 1,516,903 shares, calculated from 49,236,365 shares outstanding as of April 28, 2025. The shares are held directly by RTW Funds, for which RTW Investments acts as investment adviser, and Dr. Wong is identified as Managing Partner and Chief Investment Officer with shared voting and dispositive power over the reported position. The statement affirms the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Because the position is below 5%, it does not cross the threshold that typically requires more detailed disclosure of control intentions.

Positive

  • None.

Negative

  • None.

Insights

RTW Funds hold a modest, non-controlling 3.1% stake in Axsome; limited immediate market impact.

The disclosed 1,516,903-share position represents 3.1% of Axsome based on the cited outstanding share count. Classification of RTW Investments as an investment adviser indicates these are fund holdings rather than a direct corporate control stake. Shared voting and dispositive power is noted, but sole powers are zero, underscoring a passive or portfolio-management posture. From a valuation perspective, this size is unlikely to move markets or alter corporate strategy absent accumulation beyond the 5% reporting threshold or activist signals.

Disclosure signals transparency but shows no immediate governance challenge given the sub-5% ownership and certification of no control intent.

The filing expressly states the securities are held in the ordinary course and not to influence control, reducing governance concerns. Shared voting/dispositive power exists through RTW Funds, and Dr. Wong is identified as the funds managing partner and CIO, which clarifies the reporting chain. Unless the position grows or RTW expresses governance proposals, this disclosure is a routine ownership update rather than a catalyst for board-level changes.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RTW Investments, LP
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D., Managing Partner
Date:08/14/2025
Roderick Wong
Signature:s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D.
Date:08/14/2025

FAQ

How many AXSM shares does RTW Investments report owning?

RTW Investments and Roderick Wong report owning 1,516,903 AXSM shares, representing 3.1% of the class.

Who filed the Schedule 13G/A for AXSM?

The statement was filed by RTW Investments, LP (as adviser to RTW Funds) and Roderick Wong, M.D.

Does the filing indicate voting or dispositive power for the reported shares?

Yes. The filing shows 0 sole voting power and 1,516,903 shared voting power, and similarly 0 sole dispositive power with 1,516,903 shared dispositive power.

Is this ownership stake considered a control position?

No. The reported 3.1% stake is below the 5% threshold and the filing states the shares are held in the ordinary course and not to change or influence control.

On what outstanding share count is the 3.1% calculated?

The percentage is calculated using 49,236,365 shares outstanding as reported by the company.
Axsome Therapeut

NASDAQ:AXSM

AXSM Rankings

AXSM Latest News

AXSM Latest SEC Filings

AXSM Stock Data

7.53B
41.82M
15.87%
77.48%
7.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK